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Dear Sirs,
High thrombin induced clot strength in whole blood measured by thrombelas tography 
(TEG) has been associated with increased risk for recurrent thrombotic events after 
percutaneous coronary intervention (PCI) (1, 2). Whole blood TEG incorporates both the 
component of platelet aggregation by thrombin, as well as contribution of fibrin to tensile 
force of whole blood thrombus. We have recently explored the use of plasma fibrin TEG 
measured in platelet-poor plasma to examine the component of clot strength attributable to 
fibrin alone in absence of platelets (3–5). We hypothesized that high mechanical strength of 
cross linked fibrin clot is associated with increased risk of recurrent myocardial infarction 
(MI) and cardiovascular death (CVD).
We enrolled subjects before or in follow up to a cardiac catheterisation. All subjects had 
angiographically established coronary artery disease and had undergone percutaneous 
coronary intervention. Mean time of follow-up was 2.9 years. Kaolin-activated TEG was 
performed according to the manufacturer’s instructions using platelet-poor citrate plasma 
(Haemonetics, Brain-tree, MA, USA) as previously described (3, 5, 6). The primary 
combined clinical endpoint was defined as first occurrence CVD or MI (7). Secondary 
endpoints included CVD, MI, stent thrombosis, and severe or life-threatening bleeding 
according to GUSTO criteria (8, 9). Clinical endpoints were evaluated by review of 
electronic medical records, with last known clinical follow-up as last censored time event. 
Coronary angiograms were reviewed to ascertain stent thrombosis events, available. The 
study protocol was approved by the Indiana University institutional review board and written 
informed consent was obtained from all subjects.
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A total of 270 subjects were included the analysis. The mean age of patients was 57.1 ± 9.8 
years. Details of clinical variables are available in the Suppl. Material (available online at 
www.thrombosis-online.com).
The primary endpoint of CVD and MI occurred in 14.4 % of subjects. Definite stent 
thrombosis occurred in 3 % and possible, probable, or definite stent thrombosis in 3.7 % of 
subjects. Subjects with occurrence of the primary endpoint during follow up (CVD or MI) 
had significantly higher maximal fibrin clot strength (TEGMA: 39.6 ± 7.4 vs 35.4 ± 7.4 mm; 
p=0.001) and shorter clot formation time (TEG-K: 1.14 ± 0.5 vs 1.49 ± 1.3 min; p=0.002) 
than patients without events during follow up, while time to fibrin formation was similar 
(TEG-R: 6.7 ± 2.9 vs 7.0 ± 2.9 min; p=0.55) (▶Figure 1). Patients with possible, probable, 
or definite stent thrombosis during follow up demonstrated significantly higher fibrin MA 
than subjects without stent thrombosis (TEG-MA: 43.8 ± 9.1 vs 35.7±7.3 mm; p=0.001), but 
no significant difference in TEG-K (1.1 ± 0.6 vs 1.45 ± 1.2 min; p=0.1) or TEG-R (6.6 ± 3 
vs 7 ± 3 min; p=0.67) (▶Figure 1). Patients with definite stent thrombosis during follow up 
also demonstrated significantly higher fibrin MA than subjects without stent thrombosis 
(TEG-MA: 41.5 ± 8.6 vs 35.8 ± 7.6 mm; p=0.037). Fibrinogen levels were not significantly 
different between subjects with CVD or MI versus those without events (Median 
[interquartile range]: 3.6 [2.1–5.1] vs 3.6 [2–5.2] mg/ml; p=0.95). Fibrinogen was modestly 
correlated with plasma fibrin TEG-MA (r=0.2; p=0.028).
Optimal cut-off for high fibrin clot strength (MA≥35.35 mm) was determined by receiver-
operating curve (ROC) analysis for the primary endpoint (area under curve (AUC)=0.652, 
p=0.002). The sensitivity for high MA (≥35.35 mm) was 80 % (CVD and MI) and 90 % 
(definite, probable, possible stent thrombosis), and the specificity was 52 % (CVD and MI) 
and 46 % (stent thrombosis). Subjects with high MA (≥35.35 mm) exhibited higher body 
mass index, and higher prevalence of diabetes mellitus, while there was no significant 
difference in other baseline variables (see Suppl. Material, available online at 
www.thrombosis-online.com).
Kaplan-Meier survival analysis and Cox regression analysis was performed with forward 
conditional adjustment for baseline clinical variables. Subjects with high MA demonstrated 
significantly increased risk for the primary combined endpoint of CVD and MI (adjusted 
hazard ratio [HR] (95 % confidence interval [CI]): 3.8 (1.7–8.3);p=0.001), as well as MI 
(adjusted HR (95 % CI): 3.0 (1.3–6.9); p=0.008) (▶Figure 1). In contrast, bleeding was not 
significantly different between subjects with high or low MA (adjusted HR (95 % CI): 0.21 
(0.04–1.2); p=0.082); however, bleeding events tended to occur more often in subjects with 
low MA. Four patients with low MA had intracranial bleeding events versus one patient with 
high MA who was being treated with warfarin at the time. Definite stent thrombosis 
(adjusted HR (95 % CI): 5.1 (0.7–47); p=0.145; log-rank p=0.041), as well as definite, 
probable, or possible stent thrombosis (adjusted HR (95 % CI): 6.3 (0.8–51); p=0.08; log-
rank p=0.014) occurred more often in subjects with high MA (▶Figure 1).
The results of our study indicate that subjects who experience recurrent ischemic 
cardiovascular events after PCI show increased maximal fibrin clot strength at baseline as 
compared to subjects without adverse ischaemic events. The importance of the fibrin 
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component in the prothrombotic environment of atherosclerotic cardiovascular disease is 
illustrated by the findings of Ang et al., who demonstrated an increased risk of MI after PCI 
in a cohort of subjects with increased fibrinogen, but not increased platelet reactivity during 
treatment with clopidogrel (10). Fibrinogen concentration was not significantly different 
between subjects with and without recurrent ischaemic events in our study; however, 
fibrinogen was correlated with TEG-MA. Differences in fibrin stabilisation and cross-
linking could potentially account for higher event rates in individuals with high plasma clot 
strength in our study.
The risk of stent thrombosis is significantly reduced with use of more potent P2Y12 platelet 
inhibitors, such as prasugrel and ticagrelor; however, stent thrombosis continues to occur in 
a significant number of subjects (11, 12). In addition, increased bleeding risk can be 
observed in a minority of patients, thus substantiating the need for better characterisation of 
subjects at risk with current standard medical therapy used in secondary prevention after PCI 
(11, 13). A validated ex vivo measure of intrinsic coagulation that is strongly associated with 
clinical risk of thrombosis and/or bleeding may be critical in further developing personalised 
antithrombotic treatment after PCI. TEG may be able provide such an integrated assessment 
of thrombotic risk. The functional fibrinogen assay in whole-blood TEG is similar to the 
measurement of TEG in platelet-poor plasma; however, there are some differences. In 
particular, in the functional fibrinogen assay, red blood cells are still present, but platelets are 
inhibited by addition of glycoprotein (GP)IIb/IIIa inhibitor. The functional fibrinogen assay 
thus measures the strength of clot that includes incorporated red cells, which has been shown 
to be dependent of factor XIIIa activity and fibrin α-chain crosslinking (14). In contrast, 
plasma TEG measures cross-linked fibrin strength in absence of red cells and without GPIIb/
IIIa antagonist, which could influence the final MA measurement. Functional fibrinogen 
TEG assays based on GPIIb/IIIa inhibition have also been shown to overestimate fibrin 
strength in patients with high platelet counts, possibly due to incomplete platelet inhibition 
(15).Limitations of our study that diminish the strength of our conclusions include the study 
size, the imbalance of diabetics between subjects with and without high clot strength, and 
relatively low predictive value of the cut-off for MA.
In conclusion, the results of our analysis suggest that measurement of high plasma fibrin clot 
strength by TEG may identify subjects at increased risk of recurrent CVD, MI, and stent 
thrombosis treated with standard dual antiplatelet therapy after PCI. Further studies are 
needed to examine the utility of plasma TEG in tailored antithrombotic treatment strategies 
after PCI.
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Figure 1: 
Thrombelastography (TEG) maximal fibrin clot strength (MA) in A) subjects without events 
vs subjects with cardiovascular death or MI and B) subjects without stent thrombosis vs 
subjects with possible, probable, or definite stent thrombosis during follow-up. C-E) Kaplan-
Meier survival analysis according to high MA (≥35.35 mm) vs low MA (<35.35 mm) for 
primary endpoint of CVD and MI (C), MI (D), and definite, probable, or possible stent 
thrombosis (E). Values are mean ± 95 % confidence interval.
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